Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (81-90 of 326) with videos related to

Pageof 33
Sort By:
Oncoimmunology|July 29, 2016
Melanoma driver mutations and immune therapyDouglas B Johnson, Christine M Lovly, Ryan J Sullivan, et al.
Oncotarget|October 27, 2015
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanomaNeel M Fofaria, Dennie T Frederick, Ryan J Sullivan, et al.
American Journal of Clinical Dermatology|December 5, 2024
Overcoming Resistance Mechanisms to Melanoma ImmunotherapyDavid X Zheng, David J Bozym, Giuseppe Tarantino, et al.
Melanoma Research|September 9, 2010
Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanomaAmy Frankenthaler, Ryan J Sullivan, Wei Wang, et al.
Journal of Translational Medicine|April 19, 2018
The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017Paolo A Ascierto, Corrado Caracò, Jeffrey E Gershenwald, et al.
The New England Journal of Medicine|July 12, 2013
Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanomaRyan J Sullivan, Donald P Lawrence, Jennifer A Wargo, et al.
Trends in Immunology|December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicitiesRobin Reschke, Ryan J Sullivan, Evan J Lipson, et al.
Journal of the American Academy of Dermatology|January 21, 2021
Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinomaSophia Z Shalhout, Jong Chul Park, Kevin S Emerick, et al.
Journal for Immunotherapy of Cancer|November 7, 2024
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanomaYu Jen Alexander Jan, Cho-Han Chiang, Soravis Osataphan, et al.
European Journal of Endocrinology|June 9, 2019
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitisAlexander Faje, Kerry Reynolds, Leyre Zubiri, et al.
Pageof 33

Showing results (81-90 of 326) with videos related to

Sort By:
Pageof 33
Oncoimmunology|July 29, 2016
Melanoma driver mutations and immune therapyDouglas B Johnson, Christine M Lovly, Ryan J Sullivan, et al.
Oncotarget|October 27, 2015
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanomaNeel M Fofaria, Dennie T Frederick, Ryan J Sullivan, et al.
American Journal of Clinical Dermatology|December 5, 2024
Overcoming Resistance Mechanisms to Melanoma ImmunotherapyDavid X Zheng, David J Bozym, Giuseppe Tarantino, et al.
Melanoma Research|September 9, 2010
Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanomaAmy Frankenthaler, Ryan J Sullivan, Wei Wang, et al.
Journal of Translational Medicine|April 19, 2018
The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017Paolo A Ascierto, Corrado Caracò, Jeffrey E Gershenwald, et al.
The New England Journal of Medicine|July 12, 2013
Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanomaRyan J Sullivan, Donald P Lawrence, Jennifer A Wargo, et al.
Trends in Immunology|December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicitiesRobin Reschke, Ryan J Sullivan, Evan J Lipson, et al.
Journal of the American Academy of Dermatology|January 21, 2021
Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinomaSophia Z Shalhout, Jong Chul Park, Kevin S Emerick, et al.
Journal for Immunotherapy of Cancer|November 7, 2024
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanomaYu Jen Alexander Jan, Cho-Han Chiang, Soravis Osataphan, et al.
European Journal of Endocrinology|June 9, 2019
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitisAlexander Faje, Kerry Reynolds, Leyre Zubiri, et al.
Pageof 33